Targeted treatment study for recurrent small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests different treatments based on the genetic and molecular features of your tumor. It is for people with stage IV small cell lung cancer that has returned after initial chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have stage IV small cell lung cancer that got worse after first-line chemo.
- You are well enough to be up and active (ECOG score 0-1).
- You can have a biopsy to get a tissue sample for genetic and molecular tests.
- Your liver, kidney, heart, and blood work must be within certain limits.
- If you have brain metastases, they must be treated and stable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs (YL201 and serplulimab) for people with extensive-stage small cell lung cancer who have not yet received treatment. The goal is to see if the combination helps shrink or control the cancer.
This trial tests a combination of four treatments—a new immunotherapy drug, an anti-cancer medication, chemotherapy, and targeted radiation—for people with extensive-stage small cell lung cancer that cannot be removed by surgery. The goal is to see if this combination can help control the cancer and improve survival.
This trial studies how well pembrolizumab, plinabulin, and etoposide plus platinum work as first treatment for extensive-stage small cell lung cancer. It may help some people by boosting the immune response while also attacking cancer with standard chemotherapy.
This trial tests different treatments for people with extensive-stage small cell lung cancer who have not had prior therapy. It aims to find which treatment works best based on the unique features of your cancer.
This trial compares a new drug combination (lurbinectedin with or without irinotecan) against the standard treatment (topotecan) for people whose small cell lung cancer has come back after initial chemotherapy. It aims to see if the new options work better.
This trial tests a combination of two drugs, lurbinectedin and serplulimab, as maintenance therapy after initial chemotherapy for people with extensive-stage small cell lung cancer (SCLC) that hasn't spread to the brain. The goal is to see if this approach helps keep the cancer from growing for longer.
Hear when a new SCLC, Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.